In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)
By Kim Margolin, M.D., FACP, FASCO The American Society of Clinical Oncology or ASCO is a professional organization that…
Melanoma Research
07/02/2024
In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)
By Kim Margolin, M.D., FACP, FASCO The American Society of Clinical Oncology or ASCO is a professional organization that…
|
|
06/06/2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…
|
|
04/11/2024
Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
|
04/11/2024
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…
|
|
03/15/2024
The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
|
|
02/17/2024
Iovance Biotherapeutics Announces Approval for TIL Therapy
The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
|
|
01/18/2024
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
|
|
10/23/2023
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
|
|
10/15/2023
Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
|
|
09/17/2023
Notes from the Lab: Novel targets for immune checkpoint inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
|
Recent Posts
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024
Managing Melanoma During the Holiday Season
Dec. 05, 2024
Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship
Dec. 03, 2024